Business
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the U.S. Sales of Veligrotug and VRDN-003 for the Treatment of Thyroid Eye Disease (TED)
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the U.S. Sales of V...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n\n\nDRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the U.S. Sales of Veligrotug and VRDN-003 for the Treatment of Thyroid Eye Disease (TED)\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\n–Third synthetic royalty transaction & second pre-approval deal for DRI –– Further increases portfolio exposure to rare diseases ––  Long-dated cashflows, extend portfolio duration –– DRI Healthcare to pay US$55 million upfront; up to US$300 million total investment, subject to achievement of certain milestones–\nTORONTO, Oct. 20, 2025 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (\"DRI Healthcare\"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a royalty interest in the U.S. net sales of veligrotug (formerly known as VRDN-001) and VRDN-003 from Viridian Therapeutics, Inc. (Nasdaq: VRDN) for an aggregate purchase price of up to US$300 million, including a US$55 million upfront payment and up to US$115 million in near-term clinical and regulatory milestone payments. \"This transaction reflects our continued strategy of providing bespoke solutions to partners that are developing and commercializing novel therapies for conditions with high unmet needs,\" said Ali Hedayat, CEO of DRI Healthcare.\n\n\n\n\n\n\n\nVeligrotug has shown clinically meaningful improvements across both active and chronic thyroid eye disease (\"TED\").  Veligrotug has met all primary and secondary endpoints across proptosis, Clinical Activity Score (CAS), and diplopia in each of its two pivotal phase 3 clinical trials, THRIVE-1 and THRIVE-2 for patients with active and chronic TED, respectively. The U.S. Food and Drug Administration (\"FDA\") has granted Breakthrough Therapy Designation, to veligrotug, which may shorten certain aspects of the regulatory review process, including eligibility for priority review. If approved, veligrotug will be only the second approved biologic treatment for ...